Kineta Enters Exclusivity and Right of First Offer Agreement with TuHURA Biosciences

July 8, 2024

DENVER, Colo., Jul 08, 2024 (247marketnews.com)- Kineta, Inc. (Nasdaq:KA) reported entering into an agreement that provides exclusivity and first offer rights with TuHURA Biosciences, Inc., in which Kineta will receive a $5 million Nonrefundable Payment from TuHURA, for the exclusive right to negotiate to acquire Kineta’s KVA12123 Immuno-Oncology Drug Program.

Craig W. Philips, President of Kineta, commented, “TuHURA is a Phase 3 registration stage immuno-oncology company with expertise and deep experience in the field. We believe they will make an excellent partner for this program and in advancing this novel drug program which could provide an important new treatment option for cancer patients.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (KA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.